JP2008538751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538751A5 JP2008538751A5 JP2008505990A JP2008505990A JP2008538751A5 JP 2008538751 A5 JP2008538751 A5 JP 2008538751A5 JP 2008505990 A JP2008505990 A JP 2008505990A JP 2008505990 A JP2008505990 A JP 2008505990A JP 2008538751 A5 JP2008538751 A5 JP 2008538751A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- surfactant
- particle size
- formulation
- average particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002105 nanoparticle Substances 0.000 claims 14
- 239000003381 stabilizer Substances 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 229960000607 ziprasidone Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 239000002280 amphoteric surfactant Substances 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960003474 ziprasidone hydrochloride Drugs 0.000 claims 1
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims 1
- 229960004487 ziprasidone mesylate Drugs 0.000 claims 1
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67112405P | 2005-04-13 | 2005-04-13 | |
| PCT/IB2006/001094 WO2006109183A1 (fr) | 2005-04-13 | 2006-04-10 | Formulations de depot injectables et procedes destines a assurer une liberation prolongee de compositions de nanoparticules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538751A JP2008538751A (ja) | 2008-11-06 |
| JP2008538751A5 true JP2008538751A5 (fr) | 2009-05-21 |
Family
ID=36602931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505990A Withdrawn JP2008538751A (ja) | 2005-04-13 | 2006-04-10 | ナノ粒子組成物を持続放出するための注射用デポ製剤および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193542A1 (fr) |
| EP (1) | EP1874268A1 (fr) |
| JP (1) | JP2008538751A (fr) |
| KR (1) | KR20070119678A (fr) |
| CN (1) | CN101166514A (fr) |
| AU (2) | AU2006233345A1 (fr) |
| BR (1) | BRPI0609299A2 (fr) |
| CA (1) | CA2605153A1 (fr) |
| IL (1) | IL186131A0 (fr) |
| MX (1) | MX2007012103A (fr) |
| NZ (1) | NZ561950A (fr) |
| RU (1) | RU2407529C2 (fr) |
| WO (1) | WO2006109183A1 (fr) |
| ZA (1) | ZA200708188B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| BR0115382A (pt) | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| MX2007016151A (es) * | 2005-06-20 | 2008-03-06 | Elan Pharma Int Ltd | Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos. |
| EP1901722A4 (fr) * | 2005-06-20 | 2011-06-15 | Elan Pharma Int Ltd | Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique |
| DK2175857T3 (da) * | 2007-07-12 | 2013-12-02 | Janssen R & D Ireland | Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril |
| WO2012053654A1 (fr) | 2010-10-18 | 2012-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Formulation à libération prolongée pour injection |
| SI2696848T1 (sl) | 2011-04-15 | 2020-10-30 | Janssen Pharmaceutica N.V. | Liofilizirane zdravilne nanosuspenzije |
| CN104814926A (zh) * | 2015-04-08 | 2015-08-05 | 中国药科大学 | 一种鲁拉西酮纳米混悬剂及其制备方法 |
| CN108289834A (zh) * | 2015-09-21 | 2018-07-17 | 梯瓦制药国际有限责任公司 | 缓释奥氮平制剂 |
| JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 徐放性オランザピン製剤 |
| CN109998991A (zh) * | 2019-04-28 | 2019-07-12 | 中国药科大学 | 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法 |
| KR102847306B1 (ko) * | 2021-08-13 | 2025-08-18 | 단국대학교 천안캠퍼스 산학협력단 | 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| JP2006514923A (ja) * | 2002-10-25 | 2006-05-18 | ファイザー・プロダクツ・インク | 注射可能な新規なデポ製剤 |
| AU2003300814A1 (en) * | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
-
2006
- 2006-04-10 NZ NZ561950A patent/NZ561950A/en not_active IP Right Cessation
- 2006-04-10 AU AU2006233345A patent/AU2006233345A1/en not_active Abandoned
- 2006-04-10 EP EP06744618A patent/EP1874268A1/fr not_active Withdrawn
- 2006-04-10 BR BRPI0609299-3A patent/BRPI0609299A2/pt not_active IP Right Cessation
- 2006-04-10 WO PCT/IB2006/001094 patent/WO2006109183A1/fr not_active Ceased
- 2006-04-10 CA CA002605153A patent/CA2605153A1/fr not_active Abandoned
- 2006-04-10 RU RU2007137846/15A patent/RU2407529C2/ru not_active IP Right Cessation
- 2006-04-10 KR KR1020077023308A patent/KR20070119678A/ko not_active Abandoned
- 2006-04-10 CN CNA2006800144209A patent/CN101166514A/zh active Pending
- 2006-04-10 MX MX2007012103A patent/MX2007012103A/es not_active Application Discontinuation
- 2006-04-10 JP JP2008505990A patent/JP2008538751A/ja not_active Withdrawn
- 2006-04-10 US US11/911,457 patent/US20080193542A1/en not_active Abandoned
-
2007
- 2007-09-20 IL IL186131A patent/IL186131A0/en unknown
- 2007-09-25 ZA ZA200708188A patent/ZA200708188B/xx unknown
-
2010
- 2010-05-05 AU AU2010201801A patent/AU2010201801A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538751A5 (fr) | ||
| WO2007086914A3 (fr) | Formulations de nanoparticules de clopidogrel | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| ES2526092T3 (es) | Formulaciones de olanzapina en nanopartículas inyectables | |
| JP2013542981A5 (fr) | ||
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| WO2007100466A3 (fr) | Formules de carvedilol nanoparticulé | |
| RU2007137846A (ru) | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц | |
| NZ573555A (en) | Nanoparticulate posaconazole formulations | |
| BRPI0705488A (pt) | composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem | |
| ES2935158T3 (es) | Composición farmacéutica de nilotinib | |
| JP2011006450A5 (fr) | ||
| JP2013542945A5 (fr) | ||
| JP2011518842A5 (fr) | ||
| JP2008530082A5 (fr) | ||
| JP2009527505A5 (fr) | ||
| JP2013505233A5 (fr) | ||
| NO20076628L (no) | Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser | |
| JP2015520241A5 (fr) | ||
| JP2004534739A5 (fr) | ||
| WO2008030209A3 (fr) | Compositions nanoparticulaires et à libération contrôlée comprenant un inhibiteur de l'agrégation des plaquettes | |
| JP2014534215A5 (fr) | ||
| WO2012068476A3 (fr) | Nanoparticles à base de poly(benzoate de vinyle) pour administrer des molécules | |
| WO2007146943A3 (fr) | Formulations d'inhibiteurs de kinase nanoparticulaires | |
| JP2009512691A5 (fr) |